NAVELBINE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAVELBINE (vinorelbine) is a semi-synthetic vinca alkaloid injectable chemotherapy approved in 1994 for treating solid tumors. It functions as a microtubule-disrupting agent that inhibits cell division. The drug is administered intravenously and represents a cornerstone cytotoxic agent in oncology regimens.
LOE Approaching
Established product with LOE approaching suggests mature brand team focused on lifecycle extension and generic preparation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
Started Oct 2015
120 enrolled
Breast Cancer
Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study
Started Mar 2003
35 enrolled
Carcinoma, Non-Small-Cell Lung
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
Started Mar 2001
38 enrolled
Breast Cancer
Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
40 enrolled
Previously Treated Metastatic Non-Small Cell Lung Cancer
Why This Matters for Your Career
Worked on NAVELBINE at Pierre Fabre? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.